Skip to main content
. 2020 Dec 7;13:170. doi: 10.1186/s13045-020-01013-x

Fig. 1.

Fig. 1

Overview of the clinical cohort and experimental workflow. a 16 types of treatment naïve primary human cancers (126 cancer samples, 94 tumor-matched normal adjacent tissues, and 12 normal tissues). Cancer abbreviation annotation: GBM (glioblastoma multiforme), HNSC (head and neck squamous cell carcinoma), LUAD (lung adenocarcinoma), LUSQ (lung squamous cell carcinoma), LUSC (lung small cell carcinoma), ESCA (esophagus squamous cell carcinoma), STAD (stomach adenocarcinoma), PAAD (pancreatic adenocarcinoma), COAD (colon adenocarcinoma), LIHC (liver hepatocellular carcinoma), KIRC (kidney renal clear cell carcinoma), BLCA (bladder urothelial carcinoma), PRAD (prostate adenocarcinoma), BRCA (breast invasive carcinoma), OV (ovarian high-grade serous carcinoma), and UCEC (uterine corpus endometrial carcinoma). b Experimental workflow for generating DIA-MS-based proteomic data. c The number of proteins identified in each cancer type